Clinical Trial

Escitalopram for Agitation in Alzheimer's Disease

Study Description

Escitalopram for Agitation in Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Escitalopram

5-15 mg/day (target: 15mg/day if tolerated)

Drug - Placebo

Masked placebo

Additional Information

Official Study Title

Escitalopram for Agitation in Alzheimer's Disease

Clinical Trial ID

NCT03108846

ParticipAid ID

lej9ld